Sweetser, Marianne T.
Alnylam Pharmaceuticals (United States) · Inserm · Great Ormond Street Hospital · The Royal Free Hospital · Shaare Zedek Medical Center · Bikur Cholim Hospital · Hospices Civils de Lyon · Hôpital Robert-Debré · Amsterdam University Medical Centers · University of Amsterdam
4 papers on CoChat
Most cited papers
- Verified
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
Adams, D., Gonzalez-Duarte, A., O’Riordan, W. D., Yang, C.-C., Ueda, M., Kristen, A. V., Tournev, I., Schmidt, H. H., Coelho, T., Berk, J. L., et al. (2018) · New England Journal of Medicine
Amyloidosis: Diagnosis, Treatment, OutcomesAlzheimer's disease research and treatments
Cited by 3,047
- Verified
Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria
Balwani, M., Sardh, E., Ventura, P., Peiró, P. A., Rees, D. C., Stölzel, U., Bissell, D. M., Bonkovsky, H. L., Windyga, J., Anderson, K. E., et al. (2020) · New England Journal of Medicine
Porphyrin Metabolism and DisordersNeonatal Health and Biochemistry
Cited by 608
- Verified
Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1
Garrelfs, S. F., Frishberg, Y., Hulton, S. A., Koren, M. J., O’Riordan, W. D., Cochat, P., Deschênes, G., Shasha-Lavsky, H., Saland, J. M., van’t Hoff, W. G., et al. (2021) · New England Journal of Medicine
Kidney Stones and Urolithiasis TreatmentsParathyroid Disorders and Treatments
Cited by 531
- Verified
Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study
Adams, D., Polydefkis, M., González-Duarte, A., Wixner, J., Kristen, A. V., Schmidt, H. H., Berk, J. L., Losada López, I. A., Dispenzieri, A., Quan, D., et al. (2021) · The Lancet Neurology
Amyloidosis: Diagnosis, Treatment, OutcomesAlzheimer's disease research and treatments
Cited by 158
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free